US 11357842
PD-L1 targeting DNA vaccine for cancer immunotherapy
granted A61KA61K2039/522A61K2039/523
Quick answer
US patent 11357842 (PD-L1 targeting DNA vaccine for cancer immunotherapy) held by Vaximm AG expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vaximm AG
- Grant date
- Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/522, A61K2039/523, A61K39/0011, A61K39/001104